Description

The RENOVE trial compared reduced-dose versus full-dose DOACs for extended venous thromboembolism VTE treatment in high-risk patients.

While the reduced dose cut major bleeding risk by 39% 🚨, it did not meet non-inferiority criteria for preventing VTE recurrence 🔄.